AI-driven discovery Position Carterra's Origin-1 generative AI platform as a complementary tool to their existing high-throughput HT-SPR systems, enabling faster antibody design with epitope-conditioned structure generation and developability-aware sequence design to accelerate client R&D pipelines.

Expanded HT-SPR leadership Highlight the recent 48-channel HT-SPR platform and Ultra line expansion as opportunities to upsell larger instrument footprints to mid-to-large biotech and pharma customers seeking scalable label-free screening and detailed biomolecular characterization at high throughput.

Global footprint Leverage Carterra’s geographically diverse Customer Experience Centers (San Francisco, Salt Lake City, Boston, Manchester, Munich) to target multinational biotech firms with regional demonstrations, service packages, and training programs to accelerate adoption across sites.

Therapeutic discovery focus Emphasize Carterra’s strengths in monoclonal antibodies and small-molecule screening to approach biopharma clients advancing mAb programs, ask about pipeline needs, and offer co-development engagements around screening, validation, and developability assessment.

Strategic partnerships Promote collaborations with CROs, AI/ML drug discovery platforms, and analytic partners (e.g., ACROBiosystems, IPA, Curia) to bundle high-throughput biology capabilities with existing workflows, increasing win probability for integrated discovery projects.